Lillian Siu

Lillian Siu

University of Toronto

H-index: 106

North America-Canada

Contact Lillian Siu

About Lillian Siu

Lillian Siu, With an exceptional h-index of 106 and a recent h-index of 62 (since 2020), a distinguished researcher at University of Toronto, specializes in the field of Cancer.

His recent articles reflect a diverse array of research interests and contributions to the field:

Abstract CT184: First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors

Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck

Abstract CT114: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced …

Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors

Abstract CT063: Phase Ib trial of ATR inhibitor (ATRi) tuvusertib+ ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors

Lenvatinib±Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The …

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Risk-Stratification in p16+ Oropharyngeal Cancer

Ultrasensitive Liquid Biopsy in Patients with p16-Positive Oropharyngeal Cancer Using HPV-seq

Lillian Siu Information

University	University of Toronto
Position	Princess Margaret Cancer Centre
Citations(all)	41704
Citations(since 2020)	17923
Cited By	30596
hIndex(all)	106
hIndex(since 2020)	62
i10Index(all)	420
i10Index(since 2020)	288
Email	Access Email
University Profile Page	University of Toronto
Google Scholar	View Google Scholar Profile

Lillian Siu Skills & Research Interests

Cancer

Top articles of Lillian Siu

Abstract CT184: First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors

Cancer Research

2024/4/5

Ping Hu

H-Index: 21

Lillian Siu

H-Index: 60

Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck

Cell Death & Differentiation

2024/2/26

Jinfeng Zou

H-Index: 14

David Goldstein

H-Index: 41

Aaron Hansen

H-Index: 32

John De Almeida

H-Index: 28

Andrew Hope

H-Index: 11

Ezra Hahn

H-Index: 5

Bayardo Perez-Ordonez

H-Index: 40

Zhen Zhao

H-Index: 7

Christopher Smith

H-Index: 0

Abstract CT114: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced …

Cancer Research

2024/4/5

Douglas Wilson

H-Index: 17

Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors

Cancer Discovery

2024/2/23

Zhihui Liu

H-Index: 8

Stephanie Lheureux

H-Index: 23

Ping Luo

H-Index: 6

Yong Zeng

H-Index: 16

Philip Awadalla

H-Index: 50

Abstract CT063: Phase Ib trial of ATR inhibitor (ATRi) tuvusertib+ ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors

Cancer Research

2024/4/5

Giuseppe Locatelli

H-Index: 5

Burak Kürsad Günhan

H-Index: 4

Lenvatinib±Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The …

International Journal of Radiation Oncology, Biology, Physics

2024/4/1

Marc Oliva

H-Index: 25

Ji-Won Kim

H-Index: 13

Ezra Cohen

H-Index: 54

Quynh-Thu Le

H-Index: 55

Jean-Pascal Machiels

H-Index: 41

Karen O'Hara

H-Index: 1

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Risk-Stratification in p16+ Oropharyngeal Cancer

International Journal of Radiation Oncology, Biology, Physics

2024/4/1

Zhen Zhao

H-Index: 7

Jinfeng Zou

H-Index: 14

John De Almeida

H-Index: 28

David Goldstein

H-Index: 41

John Kim

H-Index: 5

Fei-Fei Liu

H-Index: 48

Geoffrey Liu

H-Index: 4

Ultrasensitive Liquid Biopsy in Patients with p16-Positive Oropharyngeal Cancer Using HPV-seq

International Journal of Radiation Oncology* Biology* Physics

2024/4/1

Zhen Zhao

H-Index: 7

Jinfeng Zou

H-Index: 14

John De Almeida

H-Index: 28

David Goldstein

H-Index: 41

John Kim

H-Index: 5

Fei-Fei Liu

H-Index: 48

Geoffrey Liu

H-Index: 4

Health-related quality of life (HRQoL) data from KEYNOTE-412: chemoradiotherapy (CRT) with or without pembrolizumab (pembro) in patients (pts) with locally advanced head and …

International Journal of Radiation Oncology* Biology* Physics

2024/4/1

Jean-Pascal Machiels

H-Index: 41

Sercan Aksoy

H-Index: 21

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Cancer Immunology, Immunotherapy

2024/3/30

Melissa Johnson

H-Index: 3

Natalie Cook

H-Index: 18

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck …

The Lancet Oncology

2024/3/29

Jean-Pascal Machiels

H-Index: 41

Sercan Aksoy

H-Index: 21

Christian Simon

H-Index: 5

Vincent Grégoire

H-Index: 5

Bo Gao

H-Index: 10

Francesco Perri

H-Index: 6

Lorenzo Livi

H-Index: 18

Koji Matsumoto

H-Index: 8

Takashi Fujii

H-Index: 12

Sadakatsu Ikeda

H-Index: 19

Longitudinal ctDNA monitoring using a high sensitivity tumor-informed assay in patients with metastatic HR+/HER2− breast cancer receiving endocrine therapy …

Cancer Research

2024/3/22

Eitan Amir

H-Index: 46

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Oncoimmunology

2024/12/31

Miguel Martin

H-Index: 3

Tian Zhang

H-Index: 1

Niladri Roy Chowdhury

H-Index: 2

Tumor-agnostic ctDNA monitoring in patients with metastatic HR+/HER2-breast cancer receiving first-line CDK4/6 inhibitor and endocrine therapy

Cancer Research

2024/3/22

Geethika Yalamanchili

H-Index: 4

Eitan Amir

H-Index: 46

State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers

2024/6

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO. 17 and CO. 20 Randomized Clinical Trials

Clinical Cancer Research

2024/1/30

Nan Chen

H-Index: 4

Dongsheng Tu

H-Index: 48

Lillian Siu

H-Index: 60

Jeremy Shapiro

H-Index: 24

Abstract PS06-08: Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the …

Cancer Research

2024/5/2

Philippe Bedard

H-Index: 43

Eitan Amir

H-Index: 46

Lillian Siu

H-Index: 60

Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data

Eclinicalmedicine

2024/3/1

Paul Nguyen

H-Index: 2

Eitan Amir

H-Index: 46

Bishal Gyawali

H-Index: 11

Abstract CT104: Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously …

Cancer Research

2024/4/5

Martin Gutierrez

H-Index: 2

Douglas Wilson

H-Index: 17

Tumor-naive circulating tumor DNA as an early response biomarker for patients treated with immunotherapy in early phase clinical trials

JCO Precision Oncology

2023/4

Hua Bao

H-Index: 24

Xue Wu

H-Index: 5

See List of Professors in Lillian Siu University(University of Toronto)

academic-engine

Useful Links

List of top 50 universities

List of top 100 universities

List of top 500 universities

Find Professors Email

Find Universities Email

CUFinder Academic Engine